España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Roivant Sciences
ROIV
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$11.08
-0.19
-1.68%
Pre-Market: 7:32 PM EDT
Get Report
Comment
Roivant Sciences (ROIV) Forecast
News
Earnings
Roivant Sciences (ROIV) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Roivant Sciences (NASDAQ:ROIV) Stock
Roivant Sciences Stock (NASDAQ: ROIV)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, January 01, 2025
Strategic Sale: Eric Venker Decides To Exercise Options Worth $3.86M At Roivant Sciences
Benzinga Insights
Tuesday, December 03, 2024
Roivant Says Its Subsidiary Kinevant Sciences...
Benzinga Newsdesk
Monday, November 18, 2024
'I'm One Of You' – How 'Anti-Woke' Warrior Vivek Ramaswamy Became A Billionaire At Only 38
Adrian Volenik
Wednesday, November 13, 2024
The Analyst Landscape: 5 Takes On Roivant Sciences
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Roivant...
Benzinga Newsdesk
Tuesday, November 12, 2024
Roivant Sciences Q2 2025 GAAP EPS $(0.31) Mis...
Benzinga Newsdesk
Roivant Sciences Reports Q2 EPS Of $(0.31) Co...
Benzinga Newsdesk
Earnings Scheduled For November 12, 2024
Benzinga Insights
Friday, October 25, 2024
Dermavant Presents Final Data From ADORING 3 ...
Benzinga Newsdesk
Wednesday, October 23, 2024
At Roivant Sciences, Eric Venker Chooses To Exercise Options, Resulting In $782K
Benzinga Insights
Options Exercise: Eric Venker At Roivant Sciences Realizes $782K
Benzinga Insights
Friday, October 18, 2024
Price Over Earnings Overview: Roivant Sciences
Benzinga Insights
Thursday, October 03, 2024
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
Organon, Howmet Aerospace And More: CNBC's 'Final Trades'
Avi Kapoor
Monday, September 23, 2024
Roivant Sciences And Organon Announce Merger ...
Benzinga Newsdesk
Thursday, September 19, 2024
Cantor Fitzgerald Reiterates Overweight on Ro...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Roivant...
Benzinga Newsdesk
Wednesday, September 18, 2024
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Vandana Singh
Organon Will Acquire Dermavant, A Roivant Com...
Benzinga Newsdesk
Wednesday, September 11, 2024
4 Analysts Assess Roivant Sciences: What You Need To Know
Benzinga Insights
B of A Securities Maintains Neutral on Roivan...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Roivant...
Benzinga Newsdesk
Tuesday, September 10, 2024
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
Vandana Singh
Pulmovant, A Roivant Company, Announced The P...
Benzinga Newsdesk
Monday, September 09, 2024
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
Vandana Singh
Cantor Fitzgerald Reiterates Overweight on Ro...
Benzinga Newsdesk
Roivant Says Immunovant Reported Results From...
Benzinga Newsdesk
Monday, August 19, 2024
HC Wainwright & Co. Reiterates Buy on Roivant...
Benzinga Newsdesk
Thursday, August 08, 2024
Roivant Sciences shares are trading higher af...
Benzinga Newsdesk
Roivant Sciences Q1 2025 Adj. EPS $(0.17) Bea...
Benzinga Newsdesk
Wednesday, July 10, 2024
Piper Sandler Maintains Overweight on Roivant...
Benzinga Newsdesk
Tuesday, June 18, 2024
Evaluating Roivant Sciences: Insights From 6 Financial Analysts
Benzinga Insights
Cantor Fitzgerald Reiterates Overweight on Ro...
Benzinga Newsdesk
Friday, May 31, 2024
The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Roivant...
Benzinga Newsdesk
Thursday, May 30, 2024
Roivant Sciences Q4 2024 GAAP EPS $(0.19) Bea...
Benzinga Newsdesk
Wednesday, May 22, 2024
Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What's Going On?
Vandana Singh
Thursday, April 25, 2024
Roivant And Kinevant Sciences Complete Enroll...
Benzinga Newsdesk
Monday, April 22, 2024
Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Roivant...
Benzinga Newsdesk
Wednesday, April 03, 2024
Goldman Sachs Maintains Buy on Roivant Scienc...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Roivant ...
Benzinga Newsdesk
Deutsche Bank Maintains Buy on Roivant Scienc...
Benzinga Newsdesk
Tuesday, April 02, 2024
Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study
Vandana Singh
Roivant Sciences shares are trading higher af...
Benzinga Newsdesk
Roivant Sciences Reveals Board Authorization ...
Benzinga Newsdesk
Roivant Announces Positive NEPTUNE Study Resu...
Benzinga Newsdesk
Friday, March 29, 2024
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Wednesday, March 27, 2024
Roivant Sciences shares are trading higher af...
Benzinga Newsdesk
Tuesday, March 26, 2024
Roivant Sciences To Replace Sunrun In S&P Mid...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
